Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Indian pharma leaders demand faster approvals and reforms to boost innovation and compete globally amid rising delays.
Indian pharmaceutical leaders are calling for urgent regulatory reforms to boost innovation and shift from generics to high-value drug development, citing delays in clinical trial approvals that push research overseas.
They stress the need for faster approvals, better infrastructure, and stronger industry-academia partnerships, warning India risks falling behind China in global competitiveness.
Meanwhile, the FDA has launched a pre-check pilot program to streamline drug manufacturing reviews, aiming to reduce delays and strengthen domestic production through early collaboration and inspections.
3 Articles
Los líderes farmacéuticos indios exigen aprobaciones y reformas más rápidas para impulsar la innovación y competir globalmente en medio de las crecientes demoras.